Evaluation of Clinical Relevance of Drug-Drug Interaction Alerts Prior to Implementation

被引:13
|
作者
Meslin, S. M. M. [1 ,2 ,3 ]
Zheng, W. Y. [4 ]
Day, R. O. [1 ,2 ]
Tay, E. M. Y. [1 ]
Baysari, M. T. [2 ,4 ]
机构
[1] Univ New South Wales, St Vincents Hosp, Dept Clin Pharmacol & Toxicol, Sydney, NSW, Australia
[2] Univ New South Wales, St Vincents Clin Sch, UNSW Med, Sydney, NSW, Australia
[3] Univ New South Wales, Sch Med Sci, Sydney, NSW, Australia
[4] Macquarie Univ, Ctr Hlth Syst & Safety Res, Australian Inst Hlth Innovat, Sydney, NSW, Australia
来源
APPLIED CLINICAL INFORMATICS | 2018年 / 9卷 / 04期
基金
英国医学研究理事会;
关键词
medical order entry systems; drug interactions; alert fatigue; alert systems; clinical decision support; ORDER; EPIDEMIOLOGY; SEVERITY; SOFTWARE; SYSTEM;
D O I
10.1055/s-0038-1676039
中图分类号
R-058 [];
学科分类号
摘要
Introduction Drug-drug interaction (DDI) alerts are often implemented in the hospital computerized provider order entry (CPOE) systems with limited evaluation. This increases the risk of prescribers experiencing too many irrelevant alerts, resulting in alert fatigue. In this study, we aimed to evaluate clinical relevance of alerts prior to implementation in CPOE using two common approaches: compendia and expert panel review. Methods After generating a list of hypothetical DDI alerts, that is, alerts that would have been triggered if DDI alerts were operational in the CPOE, we calculated the agreement between multiple drug interaction compendia with regards to the severity of these alerts. A subset of DDI alerts (n = 13), with associated patient information, were presented to an expert panel to reach a consensus on whether each alert should be included in the CPOE. Results There was poor agreement between compendia in their classifications of DDI severity (Krippendorff's alpha: 0.03; 95% confidence interval: -0.07 to 0.14). Only 10% of DDI alerts were classed as severe by all compendia. On the other hand, the panel reached consensus on 12 of the 13 alerts that were presented to them regarding whether they should be included in the CPOE. Conclusion Using an expert panel and allowing them to discuss their views openly likely resulted in high agreement on what alerts should be included in a CPOE system. Presenting alerts in the context of patient cases allowed panelists to identify the conditions under which alerts were clinically relevant. The poor agreement between compendia suggests that this methodology may not be ideal for the evaluation of DDI alerts. Performing preimplementation review of DDI alerts before they are enabled provides an opportunity to minimize the risk of alert fatigue before prescribers are exposed to false-positive alerts.
引用
收藏
页码:849 / 855
页数:7
相关论文
共 50 条
  • [31] THE CLINICAL RELEVANCE OF DRUG-DRUG AND DRUG-HERBAL INTERACTIONS
    Schwab, M.
    [J]. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2009, 105 : 1 - 1
  • [32] Provider and pharmacist responses to warfarin drug-drug interaction alerts: a study of healthcare downstream of CPOE alerts
    Miller, Allison M.
    Boro, Maureen S.
    Korman, Nancy E.
    Ben Davoren, J.
    [J]. JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION, 2011, 18 : I45 - I50
  • [33] Structured override reasons for drug-drug interaction alerts in electronic health records
    Wright, Adam
    McEvoy, Dustin S.
    Aaron, Skye
    McCoy, Allison B.
    Amato, Mary G.
    Kim, Hyun
    Ai, Angela
    Cimino, James J.
    Desai, Bimal R.
    El-Kareh, Robert
    Galanter, William
    Longhurst, Christopher A.
    Malhotra, Sameer
    Radecki, Ryan P.
    Samal, Lipika
    Schreiber, Richard
    Shelov, Eric
    Sirajuddin, Anwar Mohammad
    Sittig, Dean F.
    [J]. JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION, 2019, 26 (10) : 934 - 942
  • [34] Prescribers' reported acceptance and use of drug-drug interaction alerts: An Australian survey
    Baysari, Melissa T.
    Van Dort, Bethany A.
    Zheng, Wu Yi
    Li, Ling
    Hilmer, Sarah
    Westbrook, Johanna
    Day, Richard
    [J]. HEALTH INFORMATICS JOURNAL, 2022, 28 (02)
  • [35] Mechanisms and the clinical relevance of complex drug-drug interactions
    Roberts, Arthur G.
    Gibbs, Morgan E.
    [J]. CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS, 2018, 10 : 123 - 134
  • [36] Drug-Drug Interactions of FXI Inhibitors: Clinical Relevance
    Ferri, Nicola
    Colombo, Elisa
    Corsini, Alberto
    [J]. HEMATOLOGY REPORTS, 2024, 16 (01) : 151 - 163
  • [37] Drug-drug interactions in oncology - prevalence and clinical relevance
    Hinnerkort, A.
    Liekweg, A.
    Muellerleile, U.
    Tiede, S.
    Bruellke, N.
    Jaehde, U.
    [J]. ONKOLOGIE, 2010, 33 : 1 - 1
  • [38] Relevance of drug-drug Interaction in the ICU - Perceptions of Intensivists and Pharmacists
    Askari, Marjan
    Eslami, Saied
    Louws, Mathijs
    Dongelmans, Dave
    Wierenga, Peter
    Kuiper, Rob
    Abu-Hanna, Ameen
    [J]. QUALITY OF LIFE THROUGH QUALITY OF INFORMATION, 2012, 180 : 716 - 720
  • [39] Drug-drug interaction programs in clinical practice
    Pham, P. A.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 (03) : 396 - 398
  • [40] AN INTERNATIONAL EVALUATION OF DRUG-DRUG INTERACTION ALERTS THAT SHOULD BE NON-INTERRUPTIVE EN UK AND US SETTINGS
    Robertson, Alexandra
    Slight, Sarah P.
    Seger, Diane L.
    Thomas, Sarah K.
    Coleman, Jamie
    Bates, David W.
    Phansalkar, Shobha
    [J]. JOURNAL OF GENERAL INTERNAL MEDICINE, 2014, 29 : S20 - S21